Loading...
Market
How many African countries will approve lenacapavir for HIV prevention by the end of 2025?
2
Resolution / Starting Odds
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Official announcements from national health ministries in African countries
Story
Lenacapavir Injection Shows 100% Efficacy in PURPOSE-1 HIV Prevention Trial
Aug 8, 2024, 11:12 AM
A groundbreaking study has demonstrated the efficacy of lenacapavir, an antiviral drug administered as a twice-yearly injection, in preventing HIV among cisgender women. The PURPOSE-1 trial, involving more than 2,000 African women, reported that none of the participants contracted HIV after receiving lenacapavir. This study, published in the New England Journal of Medicine, highlights the potential of lenacapavir to overcome adherence challenges associated with daily oral pre-exposure prophylaxis (PrEP) and daily F/TAF. Dr. Rajesh Gandhi noted the trial's striking efficacy, suggesting a new era in HIV prevention. The injection maintains effective HIV prevention over 6 months.
View original story
Similar markets
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
South Africa • 25%
Uganda • 25%
Both countries • 25%
Neither country • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
0-10 • 25%
11-20 • 25%
21-30 • 25%
31+ • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
USA • 25%
UK • 25%
South Africa • 25%
Other • 25%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
United States • 25%
South Africa • 25%
India • 25%
Other • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%